Nidanilimab (Nadunolimab)  (Synonyms: CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab))

Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) ^[1][2].

Nidanilimab (CAN04; 20 µg/mL; murine MC38 colon cancer cells) has glycoengineered to mediate an enhanced antibody-dependent cellular cytotoxicity (ADCC, EC₅₀<1 nM)^[2].
Nidanilimab (20 µg/mL; murine MC38 colon cancer cells) blocks IL1α and IL1β signaling with IC₅₀ values of 3.9 nM and 4.1 nM, respectively.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2171061-85-9

Liquid

Colorless to light yellow

[Nidanilimab (Nadunolimab)]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Nidanilimab (Nadunolimab) on AHC2 biosensor, can bind IL-1RAcP/IL-1 R3 Protein, Human (339a.a, HEK293, His, HY-P72565) with an affinity constant of 5.812E-10 M as determined in BLI assay.

• [1]. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.

  [2]. Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.  [Content Brief]